Concordia Healthcare Corp. T.CXR.R

THE LATEST COMPANY WHO HAS A PRICING SCANDAL

[GenericAdvocate]

I am a member of an advacacy organization that is joining forces with the National Institute of Health to put pressure on drug pricing. We recently researched pricing practices of a company named Medivation - who is the latest company attacked with a pricing scandal.  Medivation shares fell 6.1% yesterday as the scandal comes to the forefront.  

We are looking at Concordia's largest considerations first.  Donnatal is the largest branded name in the product porrfolio with consideration of 329mm.  As a method of comparison Kapvay, Chapred and Ulesfia together are only given $29 mm consideration by Concordia.  Donnatal is a generic and there are three patented drugs that treat UBS that are much more expensive.  We are also tarketing the manufacturers of these three drugs that are higher who have fewer side effects than Donnatal. It these drugs come down in price, it will force downward pressure for the generics.  There are three drugs generic drugs that complete with Donnatal, with one on the FDA roster waiting to be approved.  Donnatal is $797 for a 30 day supply.  The next generic on the market presently is Amitiza at $327 - less than half of Donnatal's price.  This means that Concordia is currently enjoying a position of being the most expensive off-patent drug in the treatement of IBS.   

Currently, most IBS patients are frustrated with the lack of safe reliable and effective IBS therapies, and would like to see new options made available to them.  The next generic in cue for FDA approval will have a greater impact on the disease because it has the ablity to Prevent Symptoms, and this news will be welcomed by physicans as important in for IBS treatment.

[select1011]

This post has been removed in accordance with Community Policy

[TickerTwit]

Really? Why a mid-cap entity like CXR when there are several well-known large-cap targets? .

[visionaryfool]

If I remember correctly, the 3 that are more expense are significantly more expense to tune of thousands more per dose. Even with price reductions, I'm not sure if they'll be sub $1K so the pricing pressure is there but not to the point where its very materially lower. Also, lower prices increases volumes so IMO, people who are using Donatel will continue to use it as the middle priced

[cashflow98]

state your position on Cxr stock and then state your case. There are many untruthful statements that you have made in your post.  

[Lattice]

This post has been removed in accordance with Community Policy

[cashflow98]

you think that because u use all caps people will listen to u ?  U should state your position on Cxr and then state your case.  No worries here...Cxr will do the numbers. I have zero, I will repeat in low caps, zero doubts about that. So good luck to all. Thanks for coming out ver recently to this board. I love to hear FACTUAL posts. The rest is noise. Wish u all the best !!!

[DrugPusher]

This post has been removed in accordance with Community Policy